Product Information

Anatibant is a proline derivative.

CAS No.	209733-45-9
Product Name	Anatibant

Biological Targets

BDKRB2

* The information provided here is compiled from public sources and is for reference only.

Studies related to this compound and its mechanism of action

The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury.

Trials • Vol. 10 • 2009

PMID: 19958521 PMC: PMC2794266 DOI: 10.1186/1745-6215-10-109

Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury.

Trials • Vol. 10 • 2009

PMID: 19958522 PMC: PMC2797007 DOI: 10.1186/1745-6215-10-110

Anatibant, a selective non-peptide bradykinin B2 receptor antagonist, reduces intracranial hypertension and histopathological damage after experimental traumatic brain injury.

Neuroscience letters • Vol. 454, Issue 2 • 2009

PMID: 19429066 DOI: 10.1016/j.neulet.2009.02.014

Inhibition of bradykinin B2 receptors before, not after onset of experimental subarachnoid hemorrhage prevents brain edema formation and improves functional outcome.

Critical care medicine • Vol. 37, Issue 7 • 2009

PMID: 19487935 DOI: 10.1097/CCM.0b013e3181a068fc

Anatibant

CAS No.	209733-45-9
MDL No.	N/A
MF	C₃₄H₃₆Cl₂N₆O₅S
MW	711.70
InChI Key	XUHBBTKJWIBQMY-MHZLTWQESA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Anatibant is a proline derivative.

CAS No.	209733-45-9
Product Name	Anatibant

Biological Targets

BDKRB2

* The information provided here is compiled from public sources and is for reference only.

Anatibant

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Anatibant

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Documentation

Anatibant

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Related Articles

The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury.

Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury.

Anatibant, a selective non-peptide bradykinin B2 receptor antagonist, reduces intracranial hypertension and histopathological damage after experimental traumatic brain injury.

Inhibition of bradykinin B2 receptors before, not after onset of experimental subarachnoid hemorrhage prevents brain edema formation and improves functional outcome.

Similar Products

(deltaS)-delta-Amino-4-((4-(((2,4-dichloro-3-(((2,4-dimethyl-8-quinolinyl)oxy)methyl)phenyl)sulfonyl)amino)tetrahydro-2H-pyran-4-yl)carbonyl)-N,N,N-trimethyl-epsilon-oxo-1-piperazinepentanaminium

Anatibant

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Related Articles

The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury.

Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury.

Anatibant, a selective non-peptide bradykinin B2 receptor antagonist, reduces intracranial hypertension and histopathological damage after experimental traumatic brain injury.

Inhibition of bradykinin B2 receptors before, not after onset of experimental subarachnoid hemorrhage prevents brain edema formation and improves functional outcome.

Similar Products

(deltaS)-delta-Amino-4-((4-(((2,4-dichloro-3-(((2,4-dimethyl-8-quinolinyl)oxy)methyl)phenyl)sulfonyl)amino)tetrahydro-2H-pyran-4-yl)carbonyl)-N,N,N-trimethyl-epsilon-oxo-1-piperazinepentanaminium

Documentation